Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Anticoagulants Stories

2013-03-04 20:22:21

RARITAN, N.J., March 4, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) issued a second complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO(®) (rivaroxaban) for the reduction of the risk of cardiovascular events in patients with acute coronary syndrome (ACS). Janssen is evaluating the letter and will respond to the agency's questions. "We remain...

2013-02-05 08:34:57

RARITAN, N.J., Feb. 5, 2013 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) today announced a clinical collaboration agreement with Portola Pharmaceuticals, Inc. and Bayer HealthCare to evaluate the safety of PRT4445 - an investigational-stage antidote for Factor Xa inhibitors - in healthy volunteers who have been administered the oral anticoagulant XARELTO(®) (rivaroxaban). The study will evaluate several dosage strengths of PRT4445 and its ability to reverse the anticoagulant...

2013-01-03 20:20:35

FRAMINGHAM, Mass., Jan. 3, 2013 /PRNewswire/ -- GTC Biotherapeutics announced today that it has changed its name to rEVO Biologics. The name change reflects the recent commercial growth of the company, and better aligns with the company's business strategy of evolving recombinant medicine for the treatment of rare diseases. (Logo: http://photos.prnewswire.com/prnh/20130103/NE36742LOGO ) "Our company is taking a revolutionary approach to the development of recombinant therapies, as...

2012-12-08 16:20:18

ATLANTA, Dec. 8, 2012 /PRNewswire-USNewswire/ -- Studies presented today at the 54th( )Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes. The studies evaluate long-held treatment standards and whether modifications in intensity and duration of therapy may offer equally effective outcomes while reducing toxicities and relapse rates. Although significant advances have been made...

2012-11-13 08:25:31

-- Coronary or Peripheral Artery Disease patients carry significant risk of fatal or debilitating myocardial infarction and stroke -- Rivaroxaban is the first novel oral anticoagulant currently under investigation in this high risk patient population -- 20,000-patient study will be conducted in collaboration with Canada's Population Health Research Institute (PHRI), representing one of the largest clinical...

2012-11-02 19:22:28

RARITAN, N.J., Nov. 2, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. (Janssen) today announced the U.S. Food and Drug Administration (FDA) has approved XARELTO(®) (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment. To view the multimedia assets associated with this release, please click:...

2012-10-25 07:30:51

TOKYO, Oct. 25, 2012 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has completed patient enrolment in the global Hokusai-VTE phase 3 study investigating the once-daily oral factor Xa inhibitor edoxaban for the treatment and prevention of recurrence of venous thromboembolism (VTE) in patients who have had an acute symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), or both.(1,2 ) Hokusai-VTE is the largest single phase 3...

2012-09-18 13:55:09

A study of patients treated with the anticoagulant medication warfarin suggests that resuming warfarin therapy after an episode of gastrointestinal tract bleeding was associated with lower risk for thrombosis (blood clot) and death, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication. Gastrointestinal tract bleeding (GIB) affects about 4.5 percent of patients treated annually with warfarin. A history of major bleeding can be a predictor...

2012-09-07 02:23:57

RARITAN, N.J., Sept. 7, 2012 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that it has submitted the Complete Response to the U.S. Food and Drug Administration (FDA) for the use of XARELTO(®) (rivaroxaban) to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS). The response includes specific information requested by the FDA in their letter issued to Janssen on June 21, 2012. Janssen also has resubmitted the...

2012-08-05 23:01:59

"Hemorrhage in the knee is now being treated with regenerative medicine at the Center for Regenerative Medicine." according to A.J. Farshchian MD an orthopedic regenerative practitioner at the center for regenerative medicine. (PRWEB) August 04, 2012 "Hemorrhage in the knee is now being treated with regenerative medicine at the Center for Regenerative Medicine." according to A.J. Farshchian MD an orthopedic regenerative practitioner at the center for regenerative medicine. Warfarin is an...